Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
以抗淀粉样蛋白抗体为基础的埃克替尼治疗阿尔茨海默病的广泛标签反映了监管机构对信恳智能的信任：分析师
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA在周二批准了礼来（纽交所LLY）的Kisunla（donanemab）一月一次注射剂用于早期症状性阿尔茨海默病成年人的静脉输液。
Once-monthly, Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.
Kisunla是唯一具有支持在去除淀粉样斑块时停止治疗的证据的淀粉样斑块靶向治疗法，这可降低治疗成本并减少输液次数。
Also Read: Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
也可阅读：为什么礼来（Eli Lilly）的股价在周二盘前上涨？
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead...
淀粉样蛋白是身体自然产生的一种蛋白质，可以聚集在一起形成...
登录免费看全文
登录/注册